Serial urinary neopterin determinations were performed in 151 patients after exeresis of a malignant melanoma. Values for patients clinically free of disease at the end of the observation were similar to those of healthy subjects. No significant varia tions were observed in patients with cutaneous meta stases. The most important variations were found in patients who developed ganglionic and above all visceral metastases. These data suggest that neopterin determination could be very useful in the follow-up of patients with a malignant melanoma and especially for detecting visceral metastases occurences.
Introduction
Neopterin is produced specifically from human macrophages when activated with interferon ga mma (1) . Urinary neopterin determination has been proven useful for the detection and for the follow-up of various malignancies (2, 3) . Only a few studies have been undertaken on the response of this marker in skin diseases (4, 5) . However, among these diseases, malignant melanoma, presents a major health problem in reason of its increasing frequency and of its ability to develop severe metastasis. Skin metastases are generally easily and rapidly detected. On the contrary, early diagnosis of ganglionic and particularly visceral (hepatic, pulmonary, cerebral) metastasis is more difficult, clinical and radiological signs being often very late.
The present paper is designed to report preliminary results of a study on the behaviour of urinary neopterin in patients treated for a malignant melanoma. Neopterin variations are also correlated with clinical evolutions of these patients in order to precise the interest of this marker in the occurrence of ganglionic and visceral metastasis.
Patients and Method
Urinary neopterin levels were measured in 151 patients (67 women and 84 men) aged 21 to 92 (mean age = 54 years). All these patients had undergone the exeresis of a malignant melanoma, confirmed by histological investigation. When the tumor was more than 3 mm thick, the surgery was followed by a polychemotherapy consisting of vincristin, dacarbazin, lomustin and dactinomycin. Urinary neopterin was measured by high performance liquid chromatography (6) once a term and each time a change in the clinical status occurred. The results were expressed in \lmol of neopterin per mol of creatinine and were compared with normal values reported in a previous study (7): 131 ± 20 v mol of neopterin per mol of creatinine.
The Student's t-test was used for statistical evaluation .
Results

Patients supposed to be in complete remission
Fifteen months after the beginning of this study, 123 patients (82% of our patients group) were clinically free of disease. The mean neopterin levels found in these patients were 188 ± 84 \lmol/mol creatinine (209 determinations). These values are not significantly different from normal values. Furthermore, the highest levels in this group were observed at the first determination (that is to say just after the surgery), or in patients whose tumors were more than 3 mm thick.
Neopterin and metastasis occurrences
Ganglionic metastasis occurred in ten patients, skin metastasis in six subjects and twelve patients developed a visceral metastasis, hepatic (n = 4), pulmonary (n = 5), cerebral (n = 1) or osseous (n = 2). one lung metastasis which vanished after surgery and cytostatic treatment, one liver metastasis and one cerebral metastasis both leading to the death of the patient.
In the four cases, neopterin values were, just after exeresis, normal or very little enhanced. In the patient who was clinically free of disease up to the end of the observation, neopterin excretion remained stable and within normal values. In liver and cerebral metastasis cases, an important and constant increase in neopterin levels was observed and the patients died from cancer respectively eight and seven months later. In the patient who experienced a lung metastasis, the Figure shows a rise of neopterin concentrations until the eighth month, when the tumor was diagnosed and excised. Three months later, this patient remained without any clinical evidence of tumor recurrence and neopterin values dropped into the normal range.
Discussion
Altered neopterin excretion has been reported in various malignancies such as haematological (8) or gynaecological cancers (9), multiple myeloma (10) . From most of these studies it emerges that assessment of neopterin may be useful in the follow-up of many types of cancer. Our preliminary results in patients with malignant melanoma support this concept.
Low neopterin levels were found in patients supposed to be in complete remission, though slightly higher than normal values. This may be explained by some enhanced post-surgery neopterin values, by the occurrence of temporary infections, and above all by a wrong classification in complete remission for some patients. Skin metastasis were associated with no significantly increased neopterin concentrations. These findings do not agree with those of Zitko (5) . However, they are not surprising in regard of the restricted localization of the disease and consequently of the weak influence on general metabolism. Furthermore, in these cases, there is no need of biological index since direct observation allows an early skin metastasis diagnosis .
The increased neopterin excretion revealed in patients who developed ganglionic metastasis bears witness to the activation of cellular immunity generally associated with these clinical events (11) . This would be a precious tool for the detection of deep ganglionic metastasis.
But the most interesting findings of this study were the very high neopterin levels always found in visceral metastasis as well as the good correlation between neopterin patterns and clinical evolution. Moreover in every case, neopterin increases preceded clinical manifestations by many weeks or months. Although the neopterin rise is not specific for any of these complications, its monthly or termly determination would enable one to discriminate between patients who are developing ganglionic or visceral metastasis and those who are not.
Further results of this study would confirm these findings, would precise the delay time between neopterin increases and clinical manifestations and will have to clarify the case of some patients supposed to be in complete remission and who nevertheless present up to now an increased neopterin excretion.
